- Home
- BTMD vs ADAG Comparison
BTMD vs ADAG Comparison
Compare BTMD & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BTMD | ADAG |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.6M | 84.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BTMD | ADAG |
|---|---|---|
| Price | $2.59 | $1.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $6.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 132.4K | 71.2K |
| Earning Date | 11-05-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 270.48 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $195,645,000.00 | $103,204.00 |
| Revenue This Year | N/A | $6,983.06 |
| Revenue Next Year | $2.80 | $36.05 |
| P/E Ratio | $3.47 | ★ N/A |
| Revenue Growth | ★ 1.34 | N/A |
| 52 Week Low | $2.32 | $1.30 |
| 52 Week High | $6.70 | $3.16 |
Technical Indicators
Market Signals| Indicator | BTMD | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 43.91 |
| Support Level | $2.32 | $1.60 |
| Resistance Level | $2.90 | $2.07 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 18.29 | 30.26 |
Price Performance
Historical ComparisonAbout BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.